Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish._老虎社区_美港股上老虎

Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.

Barrons2021-07-30

Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

377tkr
·2021-07-30
Pharma stock
回复
点赞
举报
Jessyyyyy
·2021-07-30
Woohoo
回复
3
举报
收起
- WanEH:
  wow
  2021-07-30
  回复
  举报
MrMrsBean
·2021-07-30
Please like and comment. Thanks
回复
2
举报
收起
- Jessyyyyy:
  Done
  2021-07-30
  回复
  举报
Aaron89
·2021-07-30
Good to read
回复
4
举报
AJ1
·2021-07-30
Good read
回复
5
举报
LeviStrauss
·2021-07-30
all good results but stock prices drop 😔
回复
2
举报
收起
- mingliang104:
  Yea man
  2021-07-30
  回复
  举报
5c314778
·2021-07-30
Okay
回复
2
举报
179385bb
·2021-07-30
Like
回复
4
举报
收起
- Meeooww:
  like
  2021-07-30
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-30 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125537383","market":"us","top_or_hot":-1,"title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.","media":"Barrons","content":"<div>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow ...\n\n<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">网页链接</a>\n\n</div>\n","source":"lsy1601382232898","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2>Barrons</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow ...\n\n<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","article_id":"1125537383","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","pubTimestamp":1627628293,"columns":[],"sourceInfo":{"source_id":"lsy1601382232898","name":"Barrons"},"weMediaInfo":null,"summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","collect":0,"end_time":0,"defaultTopTitle":"barrons.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"默沙东的销售超出了预期，但股票正在下跌。这里有一个看涨的理由。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":806369672,"gmtCreate":1627633240496,"gmtModify":1633757584144,"author":{"id":"3582001642809284","authorId":"3582001642809284","name":"377tkr","avatar":"https://static.tigerbbs.com/25cbfadab64a300119ffe30a37937ff2","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3582001642809284","authorIdStr":"3582001642809284"},"htmlText":"Pharma stock","listText":"Pharma stock","text":"Pharma stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806369672","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806392020,"gmtCreate":1627630650460,"gmtModify":1633757607518,"author":{"id":"3587085224026177","authorId":"3587085224026177","name":"Jessyyyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3587085224026177","authorIdStr":"3587085224026177"},"htmlText":"Woohoo","listText":"Woohoo","text":"Woohoo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806392020","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5377651,"gmtCreate":1627631339987,"gmtModify":1635164247028,"authorId":4089383496572850,"author":{"id":4089383496572850,"idStr":"4089383496572850","authorId":4089383496572850,"name":"WanEH","avatar":"https://static.tigerbbs.com/3f13510c4daf7c6eff3a61591fdca817","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806392020,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"},{"id":806399567,"gmtCreate":1627630395259,"gmtModify":1633757609436,"author":{"id":"3571129545109571","authorId":"3571129545109571","name":"MrMrsBean","avatar":"https://static.tigerbbs.com/8f1ab99fec06884945521404915aec0e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3571129545109571","authorIdStr":"3571129545109571"},"htmlText":"Please like and comment. Thanks","listText":"Please like and comment. Thanks","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806399567","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5377594,"gmtCreate":1627630658812,"gmtModify":1635164250346,"authorId":3587085224026177,"author":{"id":3587085224026177,"idStr":"3587085224026177","authorId":3587085224026177,"name":"Jessyyyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806399567,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":806305178,"gmtCreate":1627630051494,"gmtModify":1633757612109,"author":{"id":"3572240863996150","authorId":"3572240863996150","name":"Aaron89","avatar":"https://static.tigerbbs.com/5de58ca222c8d49c018d29e4dbe45035","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3572240863996150","authorIdStr":"3572240863996150"},"htmlText":"Good to read","listText":"Good to read","text":"Good to read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806305178","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806978861,"gmtCreate":1627628996453,"gmtModify":1633757617044,"author":{"id":"4089519579625270","authorId":"4089519579625270","name":"AJ1","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4089519579625270","authorIdStr":"4089519579625270"},"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806978861","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806978309,"gmtCreate":1627628980801,"gmtModify":1633757617290,"author":{"id":"3576893887863470","authorId":"3576893887863470","name":"LeviStrauss","avatar":"https://static.tigerbbs.com/3ee679917ab40e40a706e287fc3464da","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3576893887863470","authorIdStr":"3576893887863470"},"htmlText":"all good results but stock prices drop 😔","listText":"all good results but stock prices drop 😔","text":"all good results but stock prices drop 😔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806978309","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5377506,"gmtCreate":1627629717858,"gmtModify":1635164258058,"authorId":4088390766152690,"author":{"id":4088390766152690,"idStr":"4088390766152690","authorId":4088390766152690,"name":"mingliang104","avatar":"https://static.tigerbbs.com/f1558c6d92782b6fb175674394d5c3ac","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806978309,"type":1,"supId":0,"prevId":0,"content":"Yea man ","text":"Yea man ","html":"Yea man "}],"langContent":"EN"},{"id":806973923,"gmtCreate":1627628793062,"gmtModify":1633757618659,"author":{"id":"3575020360100013","authorId":"3575020360100013","name":"5c314778","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575020360100013","authorIdStr":"3575020360100013"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806973923","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806970763,"gmtCreate":1627628697952,"gmtModify":1633757619252,"author":{"id":"4087793498322120","authorId":"4087793498322120","name":"179385bb","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087793498322120","authorIdStr":"4087793498322120"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806970763","repostId":1125537383,"repostType":4,"repost":{"id":"1125537383","kind":"news","pubTimestamp":1627628293,"share":"https://www.laohu8.com/m/news/1125537383?lang=zh_CN&edition=full","pubTime":"2021-07-30 14:58","market":"us","language":"en","title":"Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125537383","media":"Barrons","summary":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line","content":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.<blockquote>默克公司的销售额超出预期，但股价正在下跌。以下是看涨的1个理由。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-07-30 14:58\n\n</h4>\n</header>\n<article>\nMerck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.<blockquote>默克第二季度销售额超出华尔街预期，每股收益也符合预期，因为这家制药巨头看到对其重磅药物的需求继续快速增长，并被迫提高全年收入指引。</blockquote> Though analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.<blockquote>尽管分析师注意到该集团业绩强劲，但默克股价在纽约早盘交易中下跌1.4%。</blockquote> The back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck &amp; Co. was established as a U.S. arm in 1891.<blockquote>背景故事。其历史可以追溯到1668年，当时德国默克集团在达姆施塔特市作为一家药房成立，当代默克公司于1891年作为美国分公司成立。</blockquote> The company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.<blockquote>该公司生产的药物包括癌症治疗药物Keytruda和HPV疫苗Gardasil。上个月，默克剥离了一组非核心业务——海外销售的非专利药物、生物仿制药和女性健康部门——更名为Organon。</blockquote> When it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.<blockquote>默克公司上次公布的收益低于分析师预期时指出，Keytruda销售额强劲增长，而包括Gardasil在内的疫苗收入低于预期。更广泛的制药行业感受到了新冠肺炎疫情的压力，因为冠状病毒和社交距离措施主导的健康问题减缓了常规疫苗接种计划。</blockquote> At the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.<blockquote>6月底，默克公司首席执行官罗布·戴维斯(Rob Davis)从备受瞩目的领导人肯尼思·弗雷泽(Kenneth Frazier)手中接过了权力，后者在公司高层任职了十年。</blockquote> What’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.<blockquote>什么是新的。默克公司公布第二季度销售额为114亿美元，超过华尔街预期的接近110亿美元，比去年同期增长22%。调整后每股收益为1.31美元，符合预期，而调整后净利润为33亿美元，较2020年第二季度增长28%，略低于华尔街共识。</blockquote> Growth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.<blockquote>肿瘤部门的增长得益于Keytruda销售额的增长，增长了23%，达到42亿美元，而Gardasil则推动了疫苗的增长，在接种量普遍下滑的情况下，该药物的销售额从前一年的低点反弹至12亿美元。</blockquote> “We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.<blockquote>戴维斯在一份声明中表示：“随着疫情对我们业绩的影响减弱，我们的基础业务在主要增长动力的带动下呈现强劲势头，这让我们感到鼓舞。”</blockquote> The company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.<blockquote>该公司表示，预计全年销售额增长将在12%至14%之间，同时将2021年收入预期收窄并上调至46.4至474亿美元之间。</blockquote> Looking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.<blockquote>展望未来。这个财报季，市场似乎很挑剔：即使各行业的公司都公布了井喷式的财报，投资者也会发现可以抓住和关注的负面点。尽管业绩强劲，默克公司可能已经成为这种情绪的受害者。</blockquote> But there is reason to be bullish on the stock.<blockquote>但有理由看好该股。</blockquote> Analysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.<blockquote>Cantor Fitzgerald分析师给予默克股票跑赢大盘评级，目标价107美元。周四交易价格约为77.50美元，这表明该股还有上涨38%的空间——对于道琼斯工业指数成分股的回报率来说，这是一个不错的估计。</blockquote> “The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.<blockquote>以Louise Chen为首的分析师写道：“默克主要产品的基本收入增长突显出，肿瘤学、疫苗、动物保健和部分医院/专科护理产品的增长以及利润扩张机会仍未得到充分重视。”分析师补充说，他们特别认为Keytruda的销售预期有上升空间。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.barrons.com/articles/merck-sales-beat-estimates-but-the-stock-is-falling-heres-1-reason-to-be-bullish-51627572965?mod=hp_DAY_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125537383","content_text":"Merck’s second-quarter sales outpaced Wall Street expectations while earnings per share came in line with estimates, as the pharmaceutical giant saw demand for its blockbuster drugs continue to grow at pace and was pushed to raise full-year revenue guidance.\nThough analysts noted the strong results from the group, shares in Merck slipped 1.4% in early New York trading.\nThe back story. Tracing its roots back to 1668, when Germany’s Merck Group was founded as a pharmacy in the city of Darmstadt, the contemporary Merck & Co. was established as a U.S. arm in 1891.\nThe company makes drugs including cancer treatment Keytruda and HPV vaccine Gardasil. Last month, Merck spun off a group of non-core businesses—off-patent drugs sold overseas, biosimilars, and a women’s health division—as Organon.\nWhen it last reported earnings, which missed analyst estimates, Merck noted strong growth in Keytruda sales while revenue from its vaccines, including Gardasil, fell short of expectations. The wider drug industry has felt a pinch from the Covid-19 pandemic, as health concerns dominated by coronavirus and social distancing measures have slowed regular vaccination schedules.\nAt the end of June, Merck’s chief executive, Rob Davis, took over the reins from high-profile leader Kenneth Frazier, who spent a decade at the top of the company.\nWhat’s new. Merck reported sales of $11.4 billion in the second quarter, outpacing Wall Street estimates of closer to $11 billion and representing a 22% rise from the same period in the year prior. Adjusted earnings per share of $1.31 was in line with expectations, while adjusted net income of $3.3 billion—28% growth from the second quarter of 2020—fell just behind the Street’s consensus.\nGrowth was led in the oncology division by higher sales of Keytruda, which rose 23% to $4.2 billion, while Gardasil drove growth in vaccines, as sales of the drug rebounded to $1.2 billion from lows in the year prior amid a wider slump in inoculations.\n“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens,” Davis said in a statement.\nThe company said it expects full-year sales growth to be between 12% and 14%, while it narrowed and raised its estimates for 2021 revenue to be between $46.4 and $47.4 billion.\nLooking ahead. Markets seem picky this earnings season: Even as companies across sectors post blowout earnings, investors find negative points to grab onto and focus on. Despite strong results, Merck may have fallen victim to this sentiment.\nBut there is reason to be bullish on the stock.\nAnalysts at Cantor Fitzgerald give Merck stock an overweight rating with a target price of $107. Trading around $77.50 on Thursday, that suggests the shares have legs to climb 38% higher—not a bad estimate for returns on a Dow industrials constituent.\n“The underlying revenue growth for Merck’s key products underscores that growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, remain underappreciated,” wrote analysts led by Louise Chen. The analysts added that, in particular, they see upside in sales estimates for Keytruda.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5377408,"gmtCreate":1627628747236,"gmtModify":1635164264099,"authorId":3565581801642914,"author":{"id":3565581801642914,"idStr":"3565581801642914","authorId":3565581801642914,"name":"Meeooww","avatar":"https://static.tigerbbs.com/835877514284948977794166ddf26eba","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806970763,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":43,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}